Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6524170 | 0.84 | KDM4E (0.31) | — | |
| SCHEMBL10232878 | 0.78 | PIK3CD (0.42) | PIK3CD | |
| SCHEMBL26030797 | 0.77 | ADRB2 (0.41) | LMNACYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL14616922 | 0.77 | PDCD1 (0.31) | — | |
| SCHEMBL26030798 | 0.76 | HRH3 (0.40) | LMNACYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL7881846 | 0.76 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL26030800 | 0.75 | LMNA (0.31) | LMNACYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL3671786 | 0.73 | CYP3A4 (0.46) | LMNACYP1A2CYP2D6SCN1ASCN2A | |
| SCHEMBL30566041 | 0.73 | KDM4E (0.42) | PIK3CD | |
| SCHEMBL20079194 | 0.73 | OPRL1 (0.35) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230265104-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | NOTCH1, NOTCH2, HES1 | LMNA 2319/4885CYP1A2 2773/4885CYP2D6 3944/4885 |
| US-20230265104-A1 | NOVEL HETEROCYCLIC COMPOUNDS | MKI67, CCNI, KRAS | LMNA 3049/4885CYP1A2 2080/4885CYP2D6 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.